ArticleOncogene2004
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.
- Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.PloS one · 2017Pooled it
- Article
- Chitosan-Based Nanoparticles for Twist1 Knockdown in 4T1 Cells.Macromolecular bioscience · 2025Article
- Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer.Cancer medicine · 2024Article
- Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response.Cancer metastasis reviews · 2024Review
- Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma.BMC cancer · 2024Article
- Spatial and Temporal Relationship between Epithelial-Mesenchymal Transition (EMT) and Stem Cells in Cancer.Clinical chemistry · 2024Article
- Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases.International journal of molecular sciences · 2023Review
- CDC20 promotes radioresistance of prostate cancer by activating Twist1 expression.Apoptosis : an international journal on programmed cell death · 2023Article
- TRPM7 transactivates the FOSL1 gene through STAT3 and enhances glioma stemness.Cellular and molecular life sciences : CMLS · 2023Article
- Twist alters the breast tumor microenvironment via choline kinase to facilitate an aggressive phenotype.Molecular and cellular biochemistry · 2023Article
- Crosstalk between CaInternational journal of molecular sciences · 2022Review
- Chemotherapeutic Resistance Genes of Breast Cancer Patients - An Overview.Advanced pharmaceutical bulletin · 2022Review
- Long Noncoding RNA CRNDE Functions as an Oncogene to Facilitate Aggressive Behaviors of Nasopharyngeal Carcinoma Cells by Modulating miR-3163/TWIST1 Axis.Molecular biotechnology · 2022Article
- Identification of a novel inhibitor of liver cancer cell invasion and proliferation through regulation of Akt and Twist1.Scientific reports · 2021Article
- Lidocaine: A Local Anesthetic, Its Adverse Effects and Management.Medicina (Kaunas, Lithuania) · 2021Review
- The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.The journal of pathology. Clinical research · 2021Article
- Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.International journal of molecular sciences · 2021Article
- The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.Archives of pharmacal research · 2021Review
- Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.International journal of molecular sciences · 2020Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taxol is one of the widely used chemotherapeutic drugs against many types of human cancer. While it is considered as one of the most effective anticancer drugs, treatment failure often occurs due to development of acquired resistance. Therefore, it is important to understand the molecular mechanisms responsible for the development of drug resistance. Although it is generally believed that taxol induces cell death through interfering with microtubules leading to mitotic arrest, recent evidence has suggested that taxol-induced cell death also occurs through pathways independent of either microtubule or mitotic arrest. In this study, we report the identification of a novel role for TWIST, a basic helix-loop-helix protein, which plays a central role in cell type determination and differentiation, during generation of acquired resistance to taxol in a nasopharyngeal carcinoma cell line, HNE1-T3, using comparative genome hybridization (CGH) and subsequent RT-PCR and Western blotting. We found that upregulation of TWIST was associated with cellular resistance to taxol but not other drugs with different mechanisms of action. The fact that increased TWIST protein levels were also associated with another microtubule-targeting anticancer drug, vincristine, in four types of human cancer including nasopharyngeal, bladder, ovarian and prostate, indicates that it may play a central role in the resistance to microtubule-disrupting agents. In addition, ectopic expression of TWIST into human cancer cells also led to increased resistance to both taxol and vincristine. Our results indicate a novel mechanism that leads to resistance to microtubule-disrupting anticancer drugs through upregulation of TWIST. Our evidence provides a therapeutic strategy to overcome acquired resistance through inactivation of TWIST expression in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.